Refine by
Immune Activation Technology
8 companies found
Technologybased inHayward, CALIFORNIA (USA)
Biolog, Inc. is a privately held company that began operations in Northern California in 1984. The company’s product lines have been built upon patented technology that greatly simplifies testing of cells. Biolog’s first products were introduced in ...
ANALYZING MITOCHONDRIA AT HIGHER RESOLUTION NEW PROBES OF MITOCHONDRIAL FUNCTION. MitoPlates provide a powerful new research tool by allowing scientists to run preconfigured sets of 96 mitochondrial function assays in one experiment. ...
Technologybased inVienna, AUSTRIA
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on a proprietary arenavirus platform that is designed to reprogram the body’s immune system. We are using our non-replicating and ...
Our scientific platform includes two distinct approaches to arenavirus-based therapies: replicating and non-replicating. Our replicating technology is designed to create a stronger immune response that we believe is more appropriate for use in ...
Technologybased inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
DSP-0509 is an investigational Toll-like receptor (TLR) 7 agonist, which is hypothesized to induce cytokine production, activate cytotoxic T lymphocytes, and sustain immune-mediated antitumor ...
Technologybased inWoburn, MASSACHUSETTS (USA)
We are leading the way in developing green, enabling biotechnology and nanotechnology drug delivery platforms and enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and ...
A combination therapy consisting of PKC agonists with or without HDAC inhibitors, designed to reactivate latent HIV reservoirs so that HIV can be eliminated by antiviral therapy and eradicated from the body. HIV Latency: Although highly active ...
Technologybased inBasel, SWITZERLAND
T3 Pharmaceuticals was founded in May 2015 by Simon Ittig, Christoph Kasper, Marlise Amstutz and Helmut Kessmann as a spin-off of the University of Basel. The team has developed an efficient protein delivery technology that is based on the use of ...
T3 Pharma has developed a proprietary cancer therapy platform based on regulating and harnessing the natural behaviours of live bacteria. The genetically engineered bacteria selectively target solid tumors, where they deliver chosen protein payloads ...
Technologybased inMünchen, GERMANY
We are an interdisciplinary team with a focus on research, translation, clinical development, manufacturing, and commercialization. Our passionate team is committed to provide safe and effective tumor therapy. We are supported by a strong scientific ...
This results in an oncolytic virus platform with an excellent safety profile and effective replication kinetics. Tumor-selective replication leads to significant oncolytic activity, while fusion-based cell death adds to its potent ...
Technologybased inBasel, SWITZERLAND
Aurealis Therapeutics, a Swiss-Finnish private biopharmaceutical company, is now entering the clinical trial phase with its patented three-in-one combination product AUP-16 for chronic non-healing wounds and other regenerative diseases. The ...
Technologybased inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...